evotec_Nov23_PanOmicsDriven - 9

Kite Pharma develops and manufactures cell-based
cancer immunotherapy products that incorporate
chimeric antigen receptor (CAR)-engineered T
cells. Kite recently announced the FDA's approval
of commercial production at the company's new
facility in Frederick, MD. The new facility joins
Kite's existing manufacturing facilities in El
Segundo, CA, and Amsterdam, the Netherlands. At
these sites, specialists oversee process development,
vector manufacturing, clinical trial production, and
commercial product manufacturing.
patients are aware of and/or are being referred to
CAR T-cell therapy. ... That's why we are working
closely with advocacy groups to help inform
patients and their care partners of different treatment
options available to them and how to advocate
for themselves throughout their treatment journey. "
Shaw says that Kite works with 275-plus authorized
treatment centers around the world where
patients can receive CAR T-cell therapy. " These
hospitals, " she adds, " need to have great working
relationships with community oncologists in order
for patients to receive timely care and smoothly
transfer back to their community oncologist for
follow-up. "
According to Shaw, a fast and dependable turnaround
time also is critical. " We are proud of our
rapid and reliable 96% manufacturing success rate, "
she declares. " In the United States, for example, we
get the patients' individually made therapies back to
them in about 16 days. "
The company has two FDA-approved CAR T-cell
therapies in five indications, and it is already
building on these accomplishments. " We are
continuing to explore how we can bring innovative
cell therapies to patients in other forms of
blood cancer and [do so] earlier in their treatment
journeys, " Shaw elaborates. " With every piece of new
research, and every piece of real-world evidence
where we see patients benefiting, we inch closer to
accomplishing our goal of changing the way that
cancers, and potentially other diseases, are treated
through personalized cell therapy. "
TAKING ON CNS DISORDERS
Personalized medicine is best known for its
oncological applications, but it has applications
in other areas, too. One of these areas is neurology.
" Applications in neurology are unfolding and
attracting investment, " reports William Hagstrom,
the founder and CEO of Octave Bioscience. " Neurodegenerative
diseases like multiple sclerosis (MS),
amyotrophic lateral sclerosis, Huntington's, Parkin9
GENengnews.com
https://www.evotec.com/en https://www.genengnews.com https://www.genengnews.com
evotec_Nov23_PanOmicsDriven

Table of Contents for the Digital Edition of evotec_Nov23_PanOmicsDriven
